The high GPBAR1 activity efficacy and the optimal pharmacokinetic profile of the new compounds place the ((1,2,4-oxadiazol-5-yl)pyrrolidin-3-yl)ureidyl scaffold in an optimal fashion for further investigations to achieve drug candidates to treat GPBAR1-related metabolic disorders. Here, GPBAR1 is linked to metabolic disease.